Pfizer and the German biotechnology company BioNTech can neutralise variants of the novel coronavirus that were first reported in the UK and South Africa, a new study suggests.The research, published in the journal Nature Medicine, noted that the vaccine is effective against coronavirus variants carrying the N501Y and E484K mutations.Also Read | India should worry about its public debtAccording to the scientists, including those from the University of Texas in the US, these variants have a substitution of the amino acid building blocks that make up the viral spike protein -- the part of the virus which enables it to enter human cells.They said these mutations in the 501st and 484th positions of the protein's amino acid molecule chain.